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O B J E C T I V E S This study sought to assess, by serial computed tomography angiography (CTA), the
effect of statin treatment on coronary plaque morphology.
B A C KG ROUND In addition to the assessment of luminal stenosis, CTA also allows characterization
of plaque morphology. Large, positively remodeled plaques with large necrotic cores have been
reported as indicators of plaque instability.
METHOD S CTA was performed in 32 patients (26 men, ages 64.3 8.5 years). Of these, 24 received
ﬂuvastatin after the baseline study; 8 subjects who refused statin treatment were followed as the control
subjects. Serial imaging was performed after a median interval of 12 months. All vessels were examined
in every subject, and a 10-mm-long segment was identiﬁed for comparison before and after inter-
vention. Total plaque volume, low attenuation plaque (LAP) volume, lumen volume, and remodeling
index were calculated.
R E S U L T S In the statin-treated patients, the total plaque volume (92.3  37.7 vs. 76.4  26.5 mm3,
p  0.01) and LAP volume (4.9  7.8 vs. 1.3  2.3 mm3, p  0.01) were signiﬁcantly reduced over time;
however, there was no change in the lumen volume (63.9  25.3 vs. 65.2  26.2 mm3, p  0.59). On
the other hand, no change was observed in the CTA characteristics in the control subjects, including
total plaque volume (94.4  21.2 vs. 98.4  28.6 mm3, p  0.48), LAP volume (2.1  3.0 vs. 2.3  3.6
mm3, p  0.91), and lumen volume (80.5  20.7 vs. 75.0  16.3 mm3, p  0.26). The plaque volume
change (15.9  22.2 vs. 4.0  14.0 mm3, p  0.01) and LAP volume change (3.7  7.0 vs. 0.2  1.5
mm3, p  0.01) were signiﬁcantly greater in the statin than the control group. The lumen volume (1.3
 15.6 vs. 5.5  13.1 mm3, p  0.24) and remodeling index (2.4  6.8% vs. 0.3  6.5%, p  0.53)
did not show the signiﬁcant differences between the 2 groups. The decrease in the plaque volume was
due to reduction in the LAP volume (R  0.83, p  0.01), and was not related to any changes in the
lumen volume (R  0.21, p  0.24).
CONC L U S I O N S This preliminary study suggests that serial CTA evaluation of coronary plaques allows
for the assessment of interval change in the plaque morphology. Statin treatment results in decreases in the
plaque and necrotic core volume. The features known to be associated with plaque instability. (J Am Coll
Cardiol Img 2010;3:691–8) © 2010 by the American College of Cardiology Foundation
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692n numerous clinical trials, various 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors, or statin drugs, have been shown to
reduce both the circulating levels of atherogenic
ipoproteins and acute cardiovascular events (1–5).
mploying coronary angiographic and intravascular
maging techniques for serial examinations, it has
een demonstrated that statins retard plaque pro-
ression, or even induce regression (6–10). The
ntravascular ultrasound (IVUS) examination has
emonstrated the feasibility of actual diminution of
he lipid cores in the atherosclerotic plaques. These
avorable effects of statins mirror the experimental
ata wherein plaque stabilization becomes obvious
fter statin administration (11,12); the effect of
tatin administration is reported to be more effective
han dietary modification (12,13). The statins also
educe intraplaque inflammation, neoangiogenesis,
poptosis, and metalloproteinase expression, all of
hich indicate plaque stabilization (12–15). Recent
mprovements in computed tomography angiogra-
phy (CTA) technology have allowed char-
acterization of plaque morphology nonin-
vasively (16,17), and described positive
remodeling and large plaque and low at-
tenuation plaque (LAP) volumes as indi-
cators of plaque instability (18,19). In the
present study, we evaluated the feasibility
of using serial coronary CTA studies for
the assessment of the changes in plaque
morphology. As an example, we assessed
the efficacy of statin treatment on alter-
ations in coronary plaque morphology.
E T H O D S
atients. In this prospective, nonrandomized study,
e enrolled 32 patients who underwent coronary
TA with suspected coronary artery disease. Cor-
nary arteries were segment-wise analyzed for each
atient; the lesions with severe calcification on
TA (which precluded plaque characterization)
ere excluded. In addition, all segments with
75% luminal stenosis were not included for they
ould not be available for comparison if subjected
o intervention. Plaques with prior percutaneous
oronary intervention were also excluded for the
oss of natural vascular architecture. All 32 patients
ere statin naive and were never treated with other
ipid-lowering drugs. Twenty-four patients were
tarted on a fixed dose of fluvastatin (20 mg)
egardless of their cholesterol levels and received
hy
und
ueuvastatin for more than 6 months after the base- wine coronary CTA image acquisition (statin
roup). Eight patients who refused to accept fluva-
tatin treatment were enrolled as the control group.
erial CTA imaging was performed at least 6
onths after the baseline CTA. The lipid profile
ncluding total cholesterol, triglyceride, and high-
ensity lipoprotein cholesterol (HDL-C) levels
ere obtained at baseline and follow-up. The study
as approved by the institutional review board, and
ll patients consented voluntarily to participate in
he study protocol.
oronary CTA. Sixty-four–slice multidetector com-
uted tomography was used in this study in 15
atients, and 16-slice in the remaining 17 patients.
ollow-up images were acquired by the same ma-
hine in every subject. Sixty-four–slice computed
omography (CT) (Aquilion 64, Toshiba Medical
ystems, Otawara, Japan) angiography was per-
ormed with a collimation of 64 0.5 mm; detector
itch of 9.8 to 11.2; pixel size of 0.39  0.39 mm;
otation time of 350, 375, or 400 ms; tube current
f 400 or 450 mA; and voltage of 135 kV. For the
ontrast-enhanced scan, 60 ml of contrast media
as injected at 4.0 ml/s followed by 20 ml at 2.0
l/s. Sixteen-slice CT (Aquilion 16, Toshiba Med-
cal Systems) angiograms were performed with a
ollimation of 16 0.5 mm, detector pitch of 3.2 to
.6, pixel size of 0.39  0.39 mm, rotation time of
00 ms, tube current of 360 mA, and voltage of 135
V. For the contrast-enhanced scan, 60 ml of
ontrast media was injected at 3.0 ml/s followed by
0 ml at 1.5 ml/s with biphasic injection of a 40-ml
aline chaser at 1.5 ml/s. Scanning was manually
nitiated based on the density of contrast enhance-
ent in the left ventricle. All scans were performed
uring a single breath-hold. Patients received a
eta-blocker 1 h before the CTA if the heart rate
as more than 60 beats/min. The raw data of the
cans were reconstructed using algorithms opti-
ized for retrograde ECG-gated multislice spiral
econstruction in diastole. R-R interval was deter-
ined by the absolute number (milliseconds) from
wave to reconstruct the images at the optimal
hase. The reconstructed image data of CTA was
ransferred to a computer workstation for post-
rocessing (ZIO M900, Amin/ZIO, Tokyo, Ja-
an). The reconstructed image data of CTA were
lso transferred to Sure Plaque software (Toshiba
edical Systems) to measure the plaque volume
ased on CTA density.
laque assessment. All vessels were examined in
very patient, and a 10-mm–long vascular segmentB B R E V I A T I O N S
N D A C R O N YM S
TA computed tomograp
ngiography
DL-C high-density
ipoprotein cholesterol
VUS intravascular ultraso
AP low attenuation plaqas identified for comparison; caution was exer-
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693ised to exclude severely calcified lesions. The CT
ngiograms were pooled, and 2 observers who were
linded to the patient identity, clinical history, and
he sequence of imaging evaluated the scans to-
ether. Lesions at baseline and follow-up study
ere synchronized by using the branch points as the
andmarks. Plaque and lumen volume measure-
ents were performed using attenuation-based au-
omated (Sure Plaque [Toshiba Medical Systems])
oftware. Planimetry of the lumen and external
essel area was performed in the first step, and
n a second step, plaque characterization based
n Hounsfield units (HU). The coronary plaques
ere color coded based on HU. The software color
odes coronary plaques based on HU into LAP
30 HU), intermediate attenuation plaque (30 to
50 HU), calcified plaque (350 to 1,000 HU), and
umen (150 to 350 HU), and measures the volume
f each component. These HU ranges were defined
y our previous study based on IVUS-verified
laque components, and the 30-HU threshold for
he detection of LAP offered a sensitivity and
pecificity of 91% and 100%, respectively (19,20).
s described previously, the remodeling index (RI)
as calculated for all lesions. The outlines were
onfirmed by observers and readjusted manually if
ecessary. Although the subjective variation was not
stimated for this study, we have previously re-
orted excellent interobserver and intraobserver
ariability for plaque component characterization,
ncluding plaque attenuation and positive remodel-
ng (19). The vessel was analyzed for LAP, total
laque and lumen volume, and RI. All parameters
ere compared between baseline and follow-up.
e have previously described the plaque character-
stics that are associated with subsequent vascular
vents. The plaques with 110% positive remod-
ling index (PR) and 30-HU attenuation (LAP)
ere described as 2-feature positive plaques, which
re associated with 22% likelihood of an acute
oronary event over the next 2 years. One-feature
ositive plaques (either PR or LAP) were associated
ith 3% 2-year risk, and 2-feature negative
laques were associated with 0.5% likelihood of
n acute event. As such, the vulnerability could be
efined on the scale of 0 to 2 (2-feature positive
laques being 2) for comparison of baseline and
ollow-up CTA plaque characteristics.
tatistical analyses. Categorical variables were ex-
ressed as percentages, and the Fisher exact prob-
bility test was used for comparisons between the
tatin group and the control group at baseline mharacteristics. Continuous variables such as age,
ipid profile, and plaque or lumen volume were
xpressed as mean SD. Age and lipid profile were
ompared between the statin group and the control
roup by the analysis of unpaired Student t test, and
etween baseline and follow-up by the analysis of
aired Student t test. The paired t test was used to
ompare lipid profiles between baseline and follow-
p. Since plaque lumen and LAP volumes, and RI
ere not normally distributed at baseline, nonpara-
etric test was used for plaque and lumen compar-
son. A Wilcoxon signed rank test was used to
ompare the baseline-to-follow-up changes of
laque lumen and LAP volumes, and RI between
he statin and control groups. To compare the
aseline CTA data and the change over time, the
ann-Whitney U test was employed. Correlation
etween the change of plaque volume and each
AP volume or lumen volume were analyzed by
inear regression analysis and correlation coefficient.
he presence of 0-, 1-, and 2-feature positive
laques was also compared between the statin group
nd the control group at baseline using the Mann-
hitney U test, and between baseline and
ollow-up using the Wilcoxon signed rank test. All
values were 2-sided, and a p value of 0.05 was
onsidered statistically significant. All analyses were
erformed with SPSS-11 software (SPSS Japan
nc., Tokyo, Japan).
E S U L T S
hirty-two patients (26 men, 6 women, ages
4.3  8.5 years) were enrolled in the current study
nd underwent clinical risk profiling and a CTA
xamination. Of these 32 patients, 24 received
uvastatin, and 8 served as the control group. The
aseline clinical and CTA characteristics of both
roups are shown in Table 1. There were no
ignificant differences in patient characteristics and
ipid profiles between the statin and control groups
t baseline. Similarly, no difference was seen in the
TA characteristics. Total plaque volume (92.3 
7.7 vs. 94.4  21.2 mm3, p  0.38) and LAP
olume (4.9  7.8 vs. 2.1  3.0 mm3, p  0.19) at
he baseline were similar in the 2 groups (Fig. 1).
umen volume (63.9  25.3 vs. 80.5  20.7 mm3,
 0.02) was significantly smaller in the statin
roup. RI (102.0  7.9% vs. 109.9  9.5%, p 
.05) was similar in the 2 groups at baseline.
Post-treatment follow-up was undertaken at a
edian of 12 months (mean  SD: 14.3  7.5
onths; range 6 to 32 months) after the initial
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694tudy and statin therapy; neither side effects of
tatin treatment were observed nor were statins
iscontinued in any patient. In the statin-treated
atients, total cholesterol (203.3 31.1 vs. 189.5
6.2 mg/dl, p  0.17) and triglyceride (158.6 
4.9 vs. 149.4  114.8 mg/dl, p  0.62) decreased
y the end of follow-up and HDL-C (53.2  15.4
Table 1. Baseline Characteristics of 32 Participants
Fluvastatin
(n  24)
Age (yrs) 63.4 9.5
Men 19 (79%)
Hypertension 11 (46%)
Hyperlipidemia 4 (17%)
Diabetes mellitus 5 (21%)
Obesity (BMI 25) 3 (13%)
Smoking 4 (15%)
Previous MI 13 (50%)
Time of follow-up (months) 15.8 8.4
Lipid proﬁle
Total cholesterol (mg/dl) 203.3 31.1
Triglyceride (mg/dl) 158.6 74.9
HDL-C (mg/dl) 53.2 15.4
BMI  body mass index; HDL-C  high-density lipoprotein cholesterol; MI  m
Figure 1. Serial Change in Plaque Characteristics by CTA
The top half of the ﬁgure shows changes in the plaque characteris
the plaque volume, LAP volume, lumen volume, and remodeling in
pink bars show the net difference between the ﬁrst and second CT
plaque volume, LAP volume, lumen volume, or remodeling index b
volume is signiﬁcantly reduced in the statin group, as is the LAP vo
computed tomography angiography; F/U  follow-up; LAP  low attens. 55.7  15.6 mg/dl, p  0.29) increased, but the
evels were not statistically significantly different
rom the baseline (Table 2). Although the lipid
rofile was not significantly altered, a significant
hange was observed in the CTA-verified plaque
orphology (Fig. 1). Total plaque volume (92.3 
7.7 vs. 76.4  26.5 mm3, p  0.01) and LAP
Control
(n  8) p Value
66.9 4.0 0.33
7 (88%) 0.99
5 (63%) 0.69
1 (13%) 0.99
1 (13%) 0.99
0 (0%) 0.55
3 (38%) 0.33
2 (25%) 0.23
14.0 7.4 0.59
181.6 33.5 0.12
181.4 128.5 0.55
51.3 12.9 0.77
ardial infarction.
in individual patients. The bottom half demonstrates changes in
in the statin (green bars) and control (yellow bars) groups; the
ages. At baseline, there is no signiﬁcant difference in total
en the statin and control groups. Upon follow-up, total plaque
e. Luminal volume remains unchanged. B/L  baseline; CTA tics
dex
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etwe
lumuation plaque.
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695olume (4.9  7.8 vs. 1.3  2.3 mm3, p  0.01)
howed significant regression at follow-up com-
ared with baseline (Fig. 1). RI decreased, albeit
ot significantly, in the statin treatment group
102.0  7.9% vs. 100.3  8.0%, p  0.06). The
umen volume did not change significantly (63.9 
5.3 vs. 65.2  26.2 mm3, p  0.59) after statin
reatment. A CTA case example is presented in
igure 2.
On the other hand, in the control subjects,
either the lipid profile (total cholesterol: 181.6 
3.5 vs. 188.0  37.5 mg/dl, p  0.60, triglyceride:
81.4  128.5 vs. 151.1  121.9 mg/dl, p  0.62,
DL-C: 51.3  12.9 vs. 56.9  17.0 mg/dl, p 
.06), nor the CTA characteristics (total plaque
olume: 94.4  21.2 vs. 98.4  28.6 mm3, p 
.48; LAP volume: 2.1  3.0 vs. 2.3  3.6 mm3,
 0.91; lumen volume: 80.5  20.7 vs. 75.0 
6.3 mm3, p  0.26; RI: 109.9  9.5 vs. 109.6 
.0%, p  0.87) changed. The plaque volume
hange (15.9  22.2 vs. 4.0  14.0 mm3, p 
Table 2. Lipid Proﬁle at Baseline and Follow-Up
Lipid Proﬁle Baseline
Statin group
Total cholesterol (mg/dl) 203.3 31.1
Triglyceride (mg/dl) 158.6 74.9
HDL-C (mg/dl) 53.2 15.4
Control group
Total cholesterol (mg/dl) 181.6 33.5
Triglyceride (mg/dl) 181.4 128.5
HDL-C (mg/dl) 51.3 12.9
HDL-C  high-density lipoprotein cholesterol.
Figure 2. Serial CTA and Plaque Characteristics Before and Afte
The upper panel shows baseline cross-sectional images of CTA, and th
plaque (blue arrow) and low attenuation plaque (red arrow) size are redu.01) and LAP volume change (3.7  7.0 vs.
.2 1.5 mm3, p 0.01) were significantly greater
n the statin than the control group. The lumen
olume (1.3  15.6 vs. 5.5  13.1 mm3, p 
.24) and RI (2.4  6.8 vs. 0.3  6.5%, p 
.53) did not show significant differences between 2
roups. There was a significant correlation between
he plaque volume change and LAP volume change
R  0.83, p  0.01) (Fig. 3). On the other hand,
o significant correlation was found between the
laque volume change and lumen volume change
R  0.21, p  0.24). The prevalence of 0- to
-feature positive plaques (based on positive re-
odeling and LAP) was not significantly different
etween the statin group and the control group
1.0  0.4 vs. 1.3  1.0, p  0.28) at baseline. In
he statin group, plaque characteristics suggestive of
nstability were significantly reduced after statin
reatment (0.6  0.5, p  0.01). On the other
and, plaque characteristics did not change signif-
cantly in the control group (1.0  0.5, p  0.32).
Follow-Up p Value
189.5 46.8 0.17
149.4 114.8 0.62
55.7 15.6 0.29
188.0 37.5 0.60
151.1 121.9 0.62
56.9 17.0 0.06
atin Treatment
wer panel shows follow-up cross-sectional images. Note that ther St
e lo
ced and the lumen (L) size enlarged after ﬂuvastatin treatment.
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696I S C U S S I O N
his pilot study demonstrates the feasibility of
mploying serial CTA examinations for clinical
rials designed to assess progression and regression
f atherosclerotic coronary artery disease. This pre-
iminary study also suggests that the use of statins
ven at a low dose may result in significant changes
n plaque morphology. Statin treatment results in
ignificant reduction of LAP volume and in turn an
bsolute decrease in plaque volume. These changes
n LAP and total plaque volume occurred when no
ignificant change was observed in the lumen size,
nd when the changes in lipid profile were not
tatistically significant. Lack of change in lipid
rofile may be due to near-normal baseline total
holesterol and triglyceride levels, lower statin dose,
nd relatively short duration of follow-up. This
uggests that the changes in the plaque morphol-
gy may even occur with relatively less robust
hanges in the lipid profile, and may occur early
on Between the Change in Plaque Volume or LAP Volume and
aque volume is almost entirely driven by a decrease in LAP vol-
there is a signiﬁcant correlation between the plaque volume
lume change (Y  0.24X  0.08, R2  0.83, p  0.01). Lower
t correlation is found between the plaque volume change and
ge (Y  0.15X  1.16, R2  0.21, p  0.24). LAP  low attenua-fter statin use. cThe observed plaque changes in response to
tatin intervention represent resolution of morpho-
ogical features associated with plaque instability.
laques susceptible to rupture are typically volumi-
ous, contain large necrotic cores, are positively
emodeled, and often covered by thin and inflamed
brous caps (20,21). It is expected that the intact
laques revealing similar characteristics would be
ulnerable to rupture and acute coronary syndrome.
n a prospective IVUS study, the plaques subse-
uently developing acute coronary events had ini-
ially exhibited a large eccentric plaque containing
n echolucent zone (22). The efficacy of statin
reatment has also been reported by serial IVUS
xaminations (4–10). The CTA noninvasively pro-
ides the qualitative and quantitative information
16–18,23,24). Our CTA follow-up study has also
emonstrated that the coronary lesions comprising
arge plaque volume, large LAP or necrotic cores,
nd positive remodeling were at significantly higher
isk of subsequent acute coronary syndrome as
ompared with the plaques that were neither posi-
ively remodeled nor contained LAP (19). The
arger the positive remodeling and the greater the
AP volume, the higher was the likelihood of an
cute event. It is reasonable to accept that a sub-
tantial reduction in LAP volume and total plaque
olume should translate into plaque stability. The
resent study proposes that CTA could potentially
e employed for the comparison of plaque size and
laque morphology at different time points and may
llow the assessment of efficacy of therapeutic
ntervention. However, the current guidelines do
ot recommend CTA for plaque assessment alone
nd certainly not for serial plaque assessment. Al-
hough it is not possible to recommend serial scans
o monitor the therapeutic efficacy of a medical
ntervention based on the present study, it at least
ndicates that plaque modulation, as a part of risk
odification, is a feasible strategy. Such a strategy
ay also be justified in a clinical trial setting.
tudy limitations. The current data only offer a pre-
iminary feasibility study, and a larger multicenter,
ultireader, multisession outcomes study will be
eeded for defining the role of imaging strategy for
emonstration of efficacy of statins in plaque stabili-
ation. In addition, since this study was not a random-
zed clinical trial, although there were no differences in
he baseline factors in the statin and control groups we
tudied, we cannot exclude the possibility of unknown
onfounders that we were unable to adjust for. It is
specially important because the IVUS studies andFigure 3. Correlati
Lumen Volume
The reduction in pl
ume. Upper panel,
change and LAP vo
panel, no signiﬁcan
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697arger populations, longer follow-up, and higher spa-
ial resolution, have demonstrated smaller changes in
laque burden. Since plaque measurement was per-
ormed semiautomatically, there is a likelihood of
easurement error, and it will be helpful to develop
ore robust automated software. Furthermore, more
otent statins or larger doses of statins would need to
e employed for better demonstration of efficacy of
tatin intervention. Similarly, follow-up scan duration
ould need to be longer and at more uniform inter-
als. Finally, demonstration of change in plaque mor-
hology by serial CTA adds significant radiation
xposure (25). In our present study, tube voltage was
35 kV, and radiation dose modulation software was
ot installed yet. For the serial CTA studies, radiation
ose is one of the most important issues to be resolved.
t the tube voltage of 135 kV, cutoff for LAP was
30 HU. Current low-dose protocols are per-
ormed at 120 kV or even at 100 kV. CTA plaque1056 – 60. 113:2826–34.esolution, may be affected by tube voltage and may
eed to be confirmed in each methodology. Fur-
hermore, the reduction in radiation dose by volt-
ge/current modulation (26), prospective gating
27,28), or limited volume scanning (29) would
ender serial imaging more acceptable.
O N C L U S I O N S
his preliminary study suggests that serial CTA
valuation of the coronary plaques allows for the
ssessment of interval changes in the plaque mor-
hology. Statin treatment results in a decrease in
he plaque and necrotic core volumes; such features
re associated with plaque instability.
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